-
Fostamatinib-Induced Hepatomegaly: A Novel Signal Identified Through US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of RefluxStop for Treatment of Chronic Gastro-esophageal Reflux Disease: A US Medicare Perspective
Sep 9, 2025, 16:22 PM -
Use of AI in Breast Cancer Screening in England Has a Minimal Impact on Greenhouse Gas Emissions and May Increase Diagnostic Accuracy
Sep 9, 2025, 16:22 PM -
Modeling the Public Health Impact of Nirsevimab and Maternal Vaccination With RSVpreF Against Infant Respiratory Syncytial Virus Infection in Germany
Sep 9, 2025, 16:22 PM -
Quo Vadis? The Emerging Role of the Medicines and Healthcare Products Regulatory Agency (MHRA) in an Evolving Regulatory Landscape
Sep 9, 2025, 16:22 PM -
Activity of the French Economic and Public Health Evaluation Committee (CEESP): Retrospective of 10 Years of Economic Assessment on Health Products
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis (CUA) of Sepiapterin for Treatment of Phenylketonuria (PKU)
Sep 9, 2025, 16:22 PM -
Real-World Data for External Controls: Insights From EMA Regulatory Submissions
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Patient-Reported Outcomes (PROs) in Asthma Biologic Late-Phase Studies and Approved Labels: Implications for Entry and Product Differentiation
Sep 9, 2025, 16:22 PM -
Financial Impact of Dementia Care on Thai Households: A Multicenter Study of Informal Care Costs and Contributing Factors
Sep 9, 2025, 16:22 PM -
A Cost-Effectiveness Evaluation of Blinatumomab Use in the Measurable Residual Disease-Negative Remission State to Treat Adults With Philadelphia-Chromosome–Negative B-cell Acute Lymphoblastic Leukemia in France
Sep 9, 2025, 16:22 PM -
Evaluating the Value Elements Considered in Health Technology Assessments of Paroxysmal Nocturnal Hemoglobinuria Treatments: A Targeted Review
Sep 9, 2025, 16:22 PM -
Economic and Clinical Impact of Advanced Therapies in Moderate-to-Severe Rheumatoid Arthritis in Spain: CIARA Study
Sep 9, 2025, 16:22 PM -
Value of the France Early Access Pathways: Highlighting Benefits for Patients and Industry Sponsors of the Novel Therapeutic Fosmanogepix Addressing High Unmet Clinical Needs in Invasive Fungal Infections
Sep 9, 2025, 16:22 PM -
Addressing Clinical Uncertainties in ATMP Reimbursement: A Review of European Methodological Guidelines and Practices
Sep 9, 2025, 16:22 PM -
Preferences for a Combination Influenza and COVID-19 Vaccine: Results From a Stated-Preference Survey With Consumers in the United States, United Kingdom, and Germany
Sep 9, 2025, 16:22 PM -
EIGER: Cost Impact of Progression to Metastatic Disease Amongst US Patients With Gastric and Gastroesophageal Junction Cancer (GCGEJC)
Sep 9, 2025, 16:22 PM -
Impact of Delayed or Missing Diagnosis of Chronic Kidney Disease
Sep 9, 2025, 16:22 PM -
Funding the Fight Against Antimicrobial Resistance: Learnings From the UK and Sweden’s Pilot Incentive Programs
Sep 9, 2025, 16:22 PM -
Advancing Cost-Effectiveness Modeling With R: A Flexible Approach for HTA Submissions
Sep 9, 2025, 16:22 PM
